|
|
USFDA Approved
drugs 2016-17
|
||||
|
|
Drug name
|
Active constituent
|
USFDA approved use
|
USFDA Approval month
|
USFDA approval year
|
|
1
|
Zepatier
|
Elbasvir + grazoprevir
|
Hepatitis C virus
|
January
|
2016
|
|
2
|
Briviact
|
Brivaracetam
|
For partial seizures (epilepsy)
|
February
|
2016
|
|
3
|
Anthim
|
Obiltoxaximab
|
For anthrax
|
March
|
2016
|
|
4
|
Taltz
|
Ixekizumab
|
For moderate to severe plaque psoriasis
|
March
|
2016
|
|
5
|
Cinqair
|
Reslizumab
|
For severe asthma
|
March
|
2016
|
|
6
|
Defitelio
|
Defibrotide sodium
|
Hepatic
veno-occlusive disease with additional kidney or lung abnormalities
|
March
|
2016
|
|
7
|
Venclexta
|
Venetoclax
|
For chronic lymphocytic leukemia in patient with chromosomal
abnormality
|
April
|
2016
|
|
8
|
Nuplazid
|
Pimavanserin
|
For treatment of hallucinations and delusions associated with
psychosis and Parkinson disease
|
April
|
2016
|
|
9
|
Tecentriq
|
Atezolizumab
|
For urothelial carcinoma (bladder cancer)
|
May
|
2016
|
|
10
|
Zinbryta
|
Daclizumab
|
For treatment of multiple sclerosis
|
May
|
2016
|
|
11
|
Ocaliva
|
Obeticholic acid
|
For treatment of rare and chronic liver disease
|
May
|
2016
|
|
12
|
Axumin
|
Fluciclovine F-18
|
As a diagnostic imaging agent to detect recurrent prostate cancer
|
May
|
2016
|
|
13
|
Netspot
|
Gallium Ga 68 dotatate
|
As a diagnostic imaging agent to detect rare neuroendocrine tumors
|
June
|
2016
|
|
14
|
Epclusa
|
Sofosbuvir and velpatasvir
|
For hepatitis C virus (for all six types)
|
June
|
2016
|
|
15
|
Xiidra
|
Liftegrast ophthalmic solution
|
For treatment of dry eye disease
|
July
|
2016
|
|
16
|
Adlyxin
|
Lixisenatide
|
For diabeties
|
July
|
2016
|
|
17
|
Exondys 51
|
Eteplirsen
|
For treatment of Duchenne muscular dystrophy
|
September
|
2016
|
|
18
|
Lartruvo
|
Olaratumab
|
For treatment of soft tissue sarcoma
|
October
|
2016
|
|
19
|
Zinplava
|
Bezlotoxumab
|
To reduce recurrence of clostridium difficle infection
|
October
|
2016
|
|
20
|
Eucrisa
|
Crisaborole
|
For treatment of eczema (atopic dermatitis)
|
December
|
2016
|
|
21
|
Rubraca
|
Rucaparib
|
For treatment of ovarian cancer
|
December
|
2016
|
|
22
|
Spinraza
|
Nusinersen
|
For treatment of spinal muscular atrophy
|
December
|
2016
|
|
23
|
Trulance
|
Plecanatide
|
For treatment of chronic idiopathic constipation
|
January
|
2017
|
|
24
|
Parsavib
|
Elelcalcetide
|
For treatment of secondary hyperparathyroidism with chronic kidney
disease
|
February
|
2017
|
|
25
|
Emflaza
|
Deflazacort
|
For treatment of Duchenne muscular dystrophy
|
February
|
2017
|
Sunday, 12 February 2017
USFDA Approved drugs 2016-17- important for NIPER exam 2017
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment